Effect of Acupoint Catgut Embedding for Middle-Aged Obesity: A Multicentre, Randomised, Sham-Controlled Trial

Table 12

Safety outcomes based on per-protocol analysis: laboratory tests.

Indictors	Time point	Abnormal (%)
		ACE group	Sham ACE group
WBC	Baseline	7 (6.54%)	2 (1.85%)	0.169
	16 weeks	4 (4.17%)	1 (1.01%)	0.347
NEU	Baseline	2 (1.87%)	3 (2.78%)	1.00
	16 weeks	1 (1.04%)	2 (2.02%)	1.00
LYM	Baseline	5 (4.67%)	6 (5.56%)	0.769
	16 weeks	2 (2.08%)	5 (5.05%)	0.466
RBC	Baseline	20 (18.69%)	17 (15.74%)	0.567
	16 weeks	17 (17.71%)	16 (16.16%)	0.773
HGB	Baseline	25 (23.36%)	19 (17.59%)	0.294
	16 weeks	22 (22.92%)	20 (20.20%)	0.645
PLT	Baseline	6 (5.61%)	3 (2.78%)	0.487
	16 weeks	6 (6.25%)	6 (6.06%)	0.956
ALT	Baseline	15 (13.89%)	16 (14.81%)	0.846
	16 weeks	14 (14.29%)	9 (9.09%)	0.256
AST	Baseline	12 (11.11%)	9 (8.33%)	0.491
	16 weeks	11 (11.22%)	9 (9.09%)	0.620
GGT	Baseline	7 (8.33%)	6 (7.14%)	0.773
	16 weeks	5 (5.38%)	9 (9.28%)	0.303
ALP	Baseline	4 (4.76%)	7 (8.33%)	0.349
	16 weeks	5 (5.32%)	7 (7.14%)	0.602
T-BIL	Baseline	16 (14.81%)	16 (14.81%)	1.000
	16 weeks	14 (14.43%)	15 (15.31%)	0.864
BUN	Baseline	4 (3.70%)	6 (5.56%)	0.517
	16 weeks	7 (7.14%)	3 (3.03%)	0.322
Cr	Baseline	28 (25.93%)	14 (12.96%)	0.016
	16 weeks	21 (21.43%)	15 (15.15%)	0.254

WBC, white blood cell; NEU, neutrophil percentage; LYM, lymphocyte percentage; RBC, red blood cell; HGB, hemoglobin; PLT, platelet; ALT, alanine aminotransferase; AST, aspartic acid aminotransferase; GGT, gamma-glutamyl transferase; ALP, alkaline phosphatase; T-BIL, total bilirubin; BUN, urea nitrogen; Cr, creatinine.